Cargando…

Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis

CONTEXT: Data quantifying the impact of metreleptin therapy on survival in non-human immunodeficiency virus (HIV)-related generalized lipodystrophy (GL) and partial lipodystrophy (PL) are unavailable. OBJECTIVE: This study aimed to estimate the treatment effect of metreleptin on survival in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cook, Keziah, Ali, Omer, Akinci, Baris, Foss de Freitas, Maria Cristina, Montenegro, Renan Magalhães, Fernandes, Virginia Oliveira, Gupta, Deepshekhar, Lou, Kai-Jye, Tuttle, Edward, Oral, Elif A, Brown, Rebecca J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Clinical Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277211/ https://www.ncbi.nlm.nih.gov/pubmed/33822100 http://dx.doi.org/10.1210/clinem/dgab216

Ejemplares similares

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

Abnormal Non Esterified Fatty Acid Suppression After a Mixed Meal Test in Patients With Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy
por: Akinci, Efe Y, et al.
Publicado: (2021)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

Inhibition of Angiopoietin-Like 3 (ANGPTL3) Reduces Adipose Tissue Insulin Resistance in Patients With Familial Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

SAT-617 Potential Utility of the Mixed Meal Test for Differential Diagnosis of Partial Lipodystrophy from Common Type 2 Diabetes and Truncal Obesity
por: Guraya, Armaan, et al.
Publicado: (2020)

SAT-622 Heterogeneity of Familial Partial Lipodystrophy Type 2 from a Genotype-Phenotype Perspective
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2020)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

Body Composition And Bone Mineral Differences According to Lamin A (LMNA) Genotype in Familial Partial Lipodystrophy Type 2
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
por: Foss-Freitas, Maria C., et al.
Publicado: (2021)

Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People
por: Özen, Samim, et al.
Publicado: (2020)

Body fat distribution in women with familial partial lipodystrophy caused by mutation in the lamin A/C gene
por: Monteiro, Luciana Z., et al.
Publicado: (2012)

PSUN138 Demonstration of Progressive Beta-Cell Failure in Familial Partial Lipodystrophy
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

SAT-574 Whole Exome Sequencing Identifies Several Variants Associated with Immune Deficiency, Inflammasomopathy and Non-Ischemic Dilated Cardiomyopathy in a Complex Case of Acquired Generalized Lipodystrophy
por: Brandao, Marjorie Azevedo Jales, et al.
Publicado: (2020)

SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges
por: Chiquette, Elaine, et al.
Publicado: (2017)

RF24 | PSUN126 A Very-Low Calorie Diet Can Reduce Insulin Resistance and Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in a Patient With Familial Partial Lipodystrophy Type 2
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

Experiences and Perspectives of Patients with Non-HIV-Associated Lipodystrophies and Their Caregivers: A Qualitative Study
por: Gomes, Aparna, et al.
Publicado: (2021)

FRI055 LYNC-LD: Prospective Multicenter Natural History Study Of Lipodystrophy Syndromes To Determine Prevalence, Incidence And Predictors Of Diabetes And Severe Hypertriglyceridemia, And Their Complications
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants
por: Eldin, Abdelwahab J., et al.
Publicado: (2018)

SUN-600 Presence of LMNA p.R582H Pathogenic Variant in Homozygous State Demonstrates Gene Dosage Effect on the Severity of Fat Loss in Lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

Homozygous LMNA p.R582H pathogenic variant reveals increasing effect on the severity of fat loss in lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
por: Jalal Eldin, Abdelwahab, et al.
Publicado: (2019)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023)

Adipocyte-Specific Deletion of Lamin A/C Largely Models Human Familial Partial Lipodystrophy Type 2
por: Corsa, Callie A.S., et al.
Publicado: (2021)

FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)

Endoplasmic reticulum stress activation in adipose tissue induces metabolic syndrome in individuals with familial partial lipodystrophy of the Dunnigan type
por: Foss-Freitas, Maria C., et al.
Publicado: (2018)

Leptin in Relation to the Lipodystrophy-Associated Metabolic Syndrome
por: Mantzoros, Christos S.
Publicado: (2012)

FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
por: Ozsu, Elif, et al.
Publicado: (2023)

Misdiagnosis of Paget’s Disease of Bone in a Congenital Generalized Lipodystrophy Patient: Case Report
por: Freire, Erika Bastos Lima, et al.
Publicado: (2021)

SARS-COV-2 infection outcomes in patients with congenital generalized lipodystrophy
por: Madeira, Mayara Ponte, et al.
Publicado: (2021)

Bone Mineral Density in Congenital Generalized Lipodystrophy: The Role of Bone Marrow Tissue, Adipokines, and Insulin Resistance
por: Freire, Erika Bastos Lima, et al.
Publicado: (2021)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

Familial partial lipodystrophy, Dunnigan variety - challenges for patient care during pregnancy: a case report
por: Belo, Sandra Patrícia Mota, et al.
Publicado: (2015)

Identifying congenital generalized lipodystrophy using deep learning-DEEPLIPO
por: da Cunha Olegario, Natália Bitar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6999usqhtp795v6ul0kqp2jo7l